Qnity partners with NVIDIA to advance semiconductor materials research

Qnity Electronics Inc. (NYSE: Q) announced a collaboration with NVIDIA to accelerate materials research and development for semiconductor applications. The partnership will utilize NVIDIA's computing technologies including Nemotron 3 Nano, ALCHEMI BMD NIM, LAMMPS Kokkos, and CUDA-X accelerated Abaqus for modeling and simulation.

The collaboration focuses on advancing materials research to support next-generation artificial intelligence, high-performance computing, and advanced packaging technologies. The companies aim to address signal integrity challenges at higher speeds and densities, which are critical for system performance and reliability.

"As AI workloads continue to grow in scale and complexity, the demand for advanced materials that deliver higher performance, quality, and reliability is increasing across the industry," said Jon Kemp, Chief Executive Officer of Qnity.

The initiative supports Qnity's focus on materials innovation across the semiconductor ecosystem, spanning chip manufacturing, advanced packaging, high-speed interconnects, and system-level integration. The collaboration is designed to help customers address evolving demands of AI-driven workloads.

Randy King, Chief Technology and Sustainability Officer at Qnity, stated that leveraging accelerated modeling allows the company to compress development timelines and bring innovation to market faster while optimizing performance factors such as signal integrity, reliability, and manufacturability.

Qnity describes itself as a technology solutions provider across the semiconductor value chain, focusing on AI, high-performance computing, and advanced connectivity applications. The company provides materials and integration expertise for semiconductor chip manufacturing and high-speed transmission systems.

You May Also Be Interested In

• Whirlpool to close Mexico plant, expects $165M restructuring cost
• AppFolio board sees departures and new appointments
• Jade Biosciences licenses antibody program from Paragon Therapeutics